We are international

References for Module 2


References for Module 2

Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;28(5):425-434.

Akpek G, Zahurak ML, Piantadosi S,et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001; v. 97, 1219.

Attal M, Harousseau JL, Facon T. Single versus double transplant in myeloma: a randomized trial of the "Inter Groupe Français Du Myélome" (IFM). Abstract Book of the VIIIth International Myeloma Workshop. May 4-8, 2001; Banff, Alberta, Canada. P28 (S15).

Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335:91-97.

Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplants in multiple myeloma patients with renal failure. Br.J Haematol. 2001;114:822-829.

Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114(3):600-607.

Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97:2574-2579.

Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999; 93(1):55-65.

Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996; 88: 2787-2793.

Bensinger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol. 2001; 38:243-249.

Berenson JR. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin Oncol. 2001; 28: 25-34.

Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99(9):3163-3168.

Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-493.

Brown JP, Hosking DJ, Ste-Marie L, et al. Risedronate, a highly effective, short term oral treatment for Paget’s disease: a dose-response study. Calcif Tissue Int. 1999; 64(2):93-99.

Callender WS, Roodman GD. Myeloma bone disease. Semin Hematol. 2001, 38: 276-285.

Cassileth P. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998; 339,1649-1656.

Cavo M, Tosi P, Zamagni E, et al. The "Bologna 96" clinical trial of single versus double PBSC transplantation for previously untreated MM: results of an interim analysis. Abstract Book of the VIIIth International Myeloma Workshop. May 4-8, 2001; Banff, Alberta, Canada. P29-30 (S16).

Coleman M, Leonard JP, Pekle K. Biaxin®, low dose thalidomide and dexamethasone (BLT-D) are highly active in multiple myeloma and Waldenström's macroglobulinemia. Abstract Book of the VIIIth International Myeloma Workshop. May 4-8, 2001; Banff, Alberta, Canada. P211 (S13).

Coleman M, Leonard JP. BLT-D (Biaxin®, low-dose thalidomide and dexamethasone) produces consistent responses in myeloma and Waldenström's macroglobulinemia. Proc ASCO. 2000(abstr): 27.

Coleman RE. Should bisphosphonates be a treatment of choice for metastatic bone disease? Semin Oncol. 2001;4(suppl 1):35-41.

Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.

Durie BGM. Low dose thalidomide in myeloma: efficacy and biologic significance. Semin Oncol. 2002;29(supp F):263-271.

Fermand JP, Marolleau JP, Albert C, et al. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD-34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Abstract Book of the VIIIth International Myeloma Workshop. May 4-8, 2001; Banff, Alberta, Canada. P147 (P61).

Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.

Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-1993 and 94-98 at European group for blood and marrow transplantation centers. Br J Haematol. 2001;113:209-216.

Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic transplantation in multiple myeloma. J Clin Oncol. 1995; 13:1312-1322.

Garban F, Attal M, Rossi JF, Payen C, Fegueux N, Sotto JJ. Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia. 2001;15:642-646.

Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992;10:334-342.

Henry DH. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia. Semin Oncol. 1998, 25: 64-68.

Klingebiel T, Schlegel, PG. GVHD: overview on pathophysiology, incidence, clinical and biological features. Bone Marrow Transplant. 1998;21(suppl 2):45.

Kooper C. Recombinant human erythropoietin in the treatment of the anemic patient with hematologic malignancies. Ann Hematol. 2001;80:319-329.

Kyle R. Update on the treatment of multiple myeloma. Oncologist. 2001;6(2):119-124.

Majolino I, Corradini P, Santoro A, et al. In multiple myeloma (MM) allogeneic PBSC transplantation results in high rate of remission and low rate of recurrence [abstract]. Blood. 2001;98(part 1):1757.

Maloney DG, Sahebi F, Stockerl-Goldstein KE, et al. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood. 2001;98(part 1):434a.

McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983; 2: 822.

Mehta J, Singhal S. Graft-versus-myeloma (review). Bone Marrow Transplant. 1998; 22:835-843.

Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed myeloma 9502 randomized trial. Blood. 2002; 99: 731-735.

Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol. 1998;16: 3832-3842.

Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH. Comparison of
melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma. Cancer. 1997;79:1561-1567.

Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.

Rajkumar SV, Hayman SR, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM). Blood. 2001;98(11):abstr 3525.

Riccardi A,Gobbi PG, Ucci G. et al. Changing clinical presentation of multiple myeloma. Eur J Cancer. 1991;27:1401-1405.

Segeren CM, Sonneveld P, van der Holt B, et al. Intensive versus double intensive therapy in previously untreated multiple myeloma: a prospective randomized phase III study in 450 patients. Abstract Book of the VIIIth International Myeloma Workshop. May 4-8, 2001; Banff, Alberta, Canada. P31 (S17).

Singhal S, Mehta J, Desikan R, et al. Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon therapy. Bone Marrow Transplant. 1999;24:13-17.

Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. NEngl J Med. 1999;341:1565-1571.

Southwest Oncology Group. SWOG-9321, INT-0141, CLB-9312 Phase III Randomized Study of L-PAM/TBI With PBSC Rescue vs VBMCP (VCR/BCNU/L-PAM/CTX/ PRED) Following Standard Induction for Previously Untreated Symptomatic Multiple Myeloma, With Further Randomization for Major Responders to IFN-_ vs Observation (summary last modified: 12/97). URL= http://www.moffitt.usf.edu/pubs/ccj/v5n1/department3.html.

Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196-1198.

 related articles